首页 > 最新文献

Human Vaccines & Immunotherapeutics最新文献

英文 中文
Exploring vaccine hesitancy and acceptance in the general population of Pakistan: Insights into COVID-19-related distress, risk perception, and stigma. 探索巴基斯坦普通人群对疫苗的犹豫不决和接受程度:洞察与 COVID-19 相关的困扰、风险认知和耻辱感。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-02-04 DOI: 10.1080/21645515.2024.2309699
Asma Omar, Iram Gul, Inayat Ali

The coronavirus disease 2019 (COVID-19) caused several impacts. Focusing on 360 participants (178 males, 182 females), this study explored the association between COVID-19 related distress, risk perception, stigma, and vaccine hesitancy and acceptance in the general population. Measures used included the Hospital Anxiety and Depression Scale (HADS) and COVID Stress Scale (CSS) to evaluate anxiety, depression, and COVID-19 related distress, the COVID-19 Risk Perception Scale and COVID-19 Stigma Discrimination Scale to assess risk perception and stigma, and the Oxford COVID-19 Vaccine Hesitancy Scale and Vaccine Acceptance Instrument to measure vaccine hesitancy and acceptance. The findings revealed that 66.9% of participants exhibited vaccine hesitancy, and stress and risk perception were significant predictors of both vaccine hesitancy and acceptance, even after controlling for demographic factors. This study highlights the importance of understanding the factors mentioned above that will contribute to vaccine hesitancy and acceptance, which will contribute to promoting vaccine acceptance.

2019年冠状病毒疾病(COVID-19)造成了多种影响。本研究以 360 名参与者(178 名男性,182 名女性)为对象,探讨了普通人群中与 COVID-19 相关的困扰、风险认知、污名化、疫苗犹豫和接受之间的关联。使用的测量方法包括:医院焦虑抑郁量表(HADS)和 COVID 压力量表(CSS),用于评估焦虑、抑郁和 COVID-19 相关困扰;COVID-19 风险感知量表和 COVID-19 耻辱歧视量表,用于评估风险感知和耻辱感;牛津 COVID-19 疫苗犹豫不决量表和疫苗接受度工具,用于测量疫苗犹豫不决和接受度。研究结果表明,66.9% 的参与者表现出疫苗犹豫不决,即使在控制了人口统计学因素后,压力和风险认知也能显著预测疫苗犹豫不决和接受程度。本研究强调了了解上述导致疫苗犹豫和接受的因素的重要性,这将有助于促进疫苗的接受。
{"title":"Exploring vaccine hesitancy and acceptance in the general population of Pakistan: Insights into COVID-19-related distress, risk perception, and stigma.","authors":"Asma Omar, Iram Gul, Inayat Ali","doi":"10.1080/21645515.2024.2309699","DOIUrl":"10.1080/21645515.2024.2309699","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) caused several impacts. Focusing on 360 participants (178 males, 182 females), this study explored the association between COVID-19 related distress, risk perception, stigma, and vaccine hesitancy and acceptance in the general population. Measures used included the Hospital Anxiety and Depression Scale (HADS) and COVID Stress Scale (CSS) to evaluate anxiety, depression, and COVID-19 related distress, the COVID-19 Risk Perception Scale and COVID-19 Stigma Discrimination Scale to assess risk perception and stigma, and the Oxford COVID-19 Vaccine Hesitancy Scale and Vaccine Acceptance Instrument to measure vaccine hesitancy and acceptance. The findings revealed that 66.9% of participants exhibited vaccine hesitancy, and stress and risk perception were significant predictors of both vaccine hesitancy and acceptance, even after controlling for demographic factors. This study highlights the importance of understanding the factors mentioned above that will contribute to vaccine hesitancy and acceptance, which will contribute to promoting vaccine acceptance.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139681808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antenatal tetanus, diphtheria, and acellular pertussis (Tdap) immunization and risk of serogroup 19 IPD in children: An indirect cohort study. 产前接种破伤风、白喉和无细胞百日咳(Tdap)疫苗与儿童罹患血清 19 型 IPD 的风险:一项间接队列研究。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-02-08 DOI: 10.1080/21645515.2024.2305522
Melina Thibault, Geneviève Deceuninck, Caroline Quach, Nicholas Brousseau

The tetanus-diphtheria-acellular pertussis (Tdap) vaccine has been indicated for pregnant women in Quebec, Canada since 2018. Recent literature suggests maternal Tdap interferes with the pneumococcal vaccine response in children exposed in utero because of maternally transferred anti-diphtheria antibodies, a phenomenon known as blunting. Using an indirect cohort study, we investigated whether maternal Tdap vaccination could alter the protection of PCV vaccines against serotype 19A/F IPD (conjugated to diphtheria toxoid in PCV10). Thirty-seven immunized IPD cases (serotype 19A/F) and 90 immunized IPD controls (non-vaccine serotypes) were analyzed using multivariate logistic regression. Our analyses did not identify antenatal Tdap exposure as a risk factor for IPD in vaccinated children, with and odds ratio close to the null (odds ratio = 0.82, 95%CI = 0.32-2.07). As this study is the first to assess the impact of maternal immunization on pneumococcal disease risk, future investigations involving a larger number of cases should be conducted to confirm or infirm our findings.

自 2018 年起,破伤风-白喉-无细胞百日咳(百白破)疫苗适用于加拿大魁北克省的孕妇。最近的文献表明,由于母体转移了抗白喉抗体,母体百白破疫苗会干扰宫内暴露儿童的肺炎球菌疫苗反应,这种现象被称为钝化。通过一项间接队列研究,我们调查了母体接种百白破疫苗是否会改变 PCV 疫苗对血清型 19A/F IPD(PCV10 中与白喉类毒素结合)的保护作用。我们使用多变量逻辑回归分析了 37 例免疫接种 IPD 病例(血清型 19A/F)和 90 例免疫接种 IPD 对照(非疫苗血清型)。我们的分析并未发现产前百白破暴露是接种疫苗儿童患 IPD 的风险因素,其几率比接近于零(几率比 = 0.82,95%CI = 0.32-2.07)。由于本研究是首次评估母体免疫接种对肺炎球菌疾病风险的影响,因此今后应进行涉及更多病例的调查,以确认或证实我们的发现。
{"title":"Antenatal tetanus, diphtheria, and acellular pertussis (Tdap) immunization and risk of serogroup 19 IPD in children: An indirect cohort study.","authors":"Melina Thibault, Geneviève Deceuninck, Caroline Quach, Nicholas Brousseau","doi":"10.1080/21645515.2024.2305522","DOIUrl":"10.1080/21645515.2024.2305522","url":null,"abstract":"<p><p>The tetanus-diphtheria-acellular pertussis (Tdap) vaccine has been indicated for pregnant women in Quebec, Canada since 2018. Recent literature suggests maternal Tdap interferes with the pneumococcal vaccine response in children exposed in utero because of maternally transferred anti-diphtheria antibodies, a phenomenon known as blunting. Using an indirect cohort study, we investigated whether maternal Tdap vaccination could alter the protection of PCV vaccines against serotype 19A/F IPD (conjugated to diphtheria toxoid in PCV10). Thirty-seven immunized IPD cases (serotype 19A/F) and 90 immunized IPD controls (non-vaccine serotypes) were analyzed using multivariate logistic regression. Our analyses did not identify antenatal Tdap exposure as a risk factor for IPD in vaccinated children, with and odds ratio close to the null (odds ratio = 0.82, 95%CI = 0.32-2.07). As this study is the first to assess the impact of maternal immunization on pneumococcal disease risk, future investigations involving a larger number of cases should be conducted to confirm or infirm our findings.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10857563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report. 一名 LCNEC 患者接受免疫疗法再治疗后病情过度进展的遗传特征探索:病例报告。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-02-13 DOI: 10.1080/21645515.2024.2313281
Yao Zhang, Jiayao Yang, Tianyu Shao, Jialu Chen, Qijin Shu, Liumei Shou

Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.

免疫检查点抑制剂(ICIs)已成为治疗大细胞神经内分泌癌(LCNEC)的一种前景广阔的疗法。然而,多项研究表明,接受 ICI 治疗的患者可能存在疾病过度进展(HPD)的潜在风险,这可能与基因改变有关。本文首次报道了一名未知的原发性LCNEC患者,该患者在接受ICI治疗(阿特珠单抗)后获得了长期应答,但由于接受了另一种ICI药物(舍普利单抗),在肿瘤进展后出现了HPD。与阿特珠单抗治疗前相比,赛鲁利单抗治疗前FAT4、SMARCA4、CYLD、CTNNB1和KIT的突变区域发生了改变。该病例表明,这些突变基因与 HPD 之间存在潜在关联。具有上述基因的患者在选择 ICI 治疗时应谨慎。这些发现需要在更大的研究队列中得到进一步证实。
{"title":"Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.","authors":"Yao Zhang, Jiayao Yang, Tianyu Shao, Jialu Chen, Qijin Shu, Liumei Shou","doi":"10.1080/21645515.2024.2313281","DOIUrl":"10.1080/21645515.2024.2313281","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10865920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The community nurse's role on the promotion of papillomavirus vaccination among young students: A study protocol. 社区护士在促进青年学生接种乳头瘤病毒疫苗方面的作用:研究方案。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-02-14 DOI: 10.1080/21645515.2024.2314383
Valentina Simonetti, Marco Tomietto, Dania Comparcini, Francesco Pastore, Pasquale Stefanizzi, Silvio Tafuri, Giancarlo Cicolini

Vaccination is the principal strategy for primary prevention of infection by Human Papilloma Virus (HPV), which causes different pathological conditions, up to cancer, in both males and females. However, to date, knowledge among adolescents and their parents about the HPV vaccine is still low. The aim of this quasi-experimental, multicenter study is to assess the effectiveness of a digital educational intervention, conducted by a multidisciplinary health-care team including a Community Nurse, to increase adolescents' HPV vaccination uptake, their knowledge, self-efficacy, feelings and involvement in HPV vaccine decision-making, and parents' vaccination hesitancy. The study will be carried out among a population of students (and their parents), aged between 11 and 13, at secondary schools in Italy. Validated questionnaires will be administered to both students and parents at baseline (T0) and 3 months after a digital educational intervention (T1). The findings may be useful in evaluating and deepening a methodology for designing and implementing educational interventions, embedded in the school setting, that could promote the achievement of outcomes within the broader process of youth's health promotion.

疫苗接种是人类乳头瘤病毒(HPV)感染初级预防的主要策略,HPV 会导致男性和女性不同的病理状况,甚至癌症。然而,迄今为止,青少年及其家长对 HPV 疫苗的了解程度仍然很低。这项准实验性多中心研究旨在评估由包括一名社区护士在内的多学科医疗团队开展的数字教育干预的效果,以提高青少年的 HPV 疫苗接种率、他们对 HPV 疫苗决策的了解、自我效能、感受和参与度,以及家长对疫苗接种的犹豫不决。这项研究将在意大利 11 至 13 岁的中学生(及其家长)中开展。将在基线(T0)和数字教育干预(T1)后 3 个月对学生和家长进行经过验证的问卷调查。研究结果将有助于评估和深化设计和实施教育干预措施的方法,这些干预措施将嵌入学校环境中,可促进在更广泛的青少年健康促进过程中取得成果。
{"title":"The community nurse's role on the promotion of papillomavirus vaccination among young students: A study protocol.","authors":"Valentina Simonetti, Marco Tomietto, Dania Comparcini, Francesco Pastore, Pasquale Stefanizzi, Silvio Tafuri, Giancarlo Cicolini","doi":"10.1080/21645515.2024.2314383","DOIUrl":"10.1080/21645515.2024.2314383","url":null,"abstract":"<p><p>Vaccination is the principal strategy for primary prevention of infection by Human Papilloma Virus (HPV), which causes different pathological conditions, up to cancer, in both males and females. However, to date, knowledge among adolescents and their parents about the HPV vaccine is still low. The aim of this quasi-experimental, multicenter study is to assess the effectiveness of a digital educational intervention, conducted by a multidisciplinary health-care team including a Community Nurse, to increase adolescents' HPV vaccination uptake, their knowledge, self-efficacy, feelings and involvement in HPV vaccine decision-making, and parents' vaccination hesitancy. The study will be carried out among a population of students (and their parents), aged between 11 and 13, at secondary schools in Italy. Validated questionnaires will be administered to both students and parents at baseline (T0) and 3 months after a digital educational intervention (T1). The findings may be useful in evaluating and deepening a methodology for designing and implementing educational interventions, embedded in the school setting, that could promote the achievement of outcomes within the broader process of youth's health promotion.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awareness, knowledge, disease prevention practices, and immunization attitude of hepatitis E virus among food handlers in Klang Valley, Malaysia. 马来西亚巴生谷食品从业人员对戊型肝炎病毒的认识、知识、疾病预防措施和免疫态度。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-03 DOI: 10.1080/21645515.2024.2318133
Sakshaleni Rajendiran, Wong Li Ping, Yuvaneswary Veloo, Syahidiah Syed Abu Thahir

Concern about the zoonotic Hepatitis E virus (HEV) is rising. Since, food handlers are at greater risk in contracting HEV, the present study aims to determine awareness, knowledge, prevention practices against HEV, and immunization attitudes. A cross sectional study was conducted among 400 food handlers in Klang Valley, Malaysia from December 2021 to March 2022. A structured questionnaire was employed for data collection and analysis with Statistical Package for Social Science (SPSS) version 29. Approximately 4.5% of the respondents (18) reported having heard of HEV, while the median scores for the knowledge and practice domains were 0/10 and 1/5, respectively. A total of 316 (79%) respondents expressed willingness to obtain vaccination if made available. This study also found that those respondents who completed their tertiary education were significantly possessed better knowledge of the disease [odd ratio (OR) = 8.95, and 95% confidence interval (CI) 4.98-16.10]. Respondents with HEV awareness reported considerably better practices (OR = 8.24, 95% CI 1.72-39.63). Food handlers with one to five years of experience in the industry expressed notable willingness to take vaccination (OR = 7.71, 95% CI 1.79-33.18). Addressing poor HEV awareness and knowledge and poor practices against the disease is crucial in enlightening the policy makers about awareness among food handlers and general population. Nonetheless, a good immunization attitude, significant acceptance toward vaccination even with the vaccine being unavailable in Malaysia, and limited awareness of HEV highlight a promising development.

人们对人畜共患的戊型肝炎病毒(HEV)的关注与日俱增。由于食品从业人员感染戊型肝炎病毒的风险较大,本研究旨在了解他们对戊型肝炎病毒的认识、知识、预防措施和免疫态度。这项横断面研究于 2021 年 12 月至 2022 年 3 月在马来西亚巴生谷的 400 名食品从业人员中进行。采用结构化问卷收集数据,并使用社会科学统计软件包(SPSS)29 版进行分析。约 4.5% 的受访者(18 人)表示听说过人乳头瘤病毒,而知识和实践领域的中位数分别为 0/10 和 1/5。共有 316 名受访者(79%)表示,如果有疫苗,他们愿意接种。本研究还发现,受过高等教育的受访者对该疾病的了解程度明显更高[奇数比 (OR) = 8.95,95% 置信区间 (CI) 为 4.98-16.10]。对高致病性乙型肝炎有认识的受访者报告的做法要好得多(OR = 8.24,95% 置信区间(CI)为 1.72-39.63)。拥有一至五年从业经验的食品从业人员表示愿意接种疫苗(OR = 7.71,95% CI 1.79-33.18)。解决对高致病性乙型肝炎认识不足、知识匮乏和操作不当的问题,对于提高政策制定者对食品从业人员和普通民众的认识至关重要。尽管如此,良好的免疫态度、对疫苗接种的极大接受度(即使马来西亚没有疫苗)以及对 HEV 的有限认识,都彰显了良好的发展前景。
{"title":"Awareness, knowledge, disease prevention practices, and immunization attitude of hepatitis E virus among food handlers in Klang Valley, Malaysia.","authors":"Sakshaleni Rajendiran, Wong Li Ping, Yuvaneswary Veloo, Syahidiah Syed Abu Thahir","doi":"10.1080/21645515.2024.2318133","DOIUrl":"10.1080/21645515.2024.2318133","url":null,"abstract":"<p><p>Concern about the zoonotic Hepatitis E virus (HEV) is rising. Since, food handlers are at greater risk in contracting HEV, the present study aims to determine awareness, knowledge, prevention practices against HEV, and immunization attitudes. A cross sectional study was conducted among 400 food handlers in Klang Valley, Malaysia from December 2021 to March 2022. A structured questionnaire was employed for data collection and analysis with Statistical Package for Social Science (SPSS) version 29. Approximately 4.5% of the respondents (18) reported having heard of HEV, while the median scores for the knowledge and practice domains were 0/10 and 1/5, respectively. A total of 316 (79%) respondents expressed willingness to obtain vaccination if made available. This study also found that those respondents who completed their tertiary education were significantly possessed better knowledge of the disease [odd ratio (OR) = 8.95, and 95% confidence interval (CI) 4.98-16.10]. Respondents with HEV awareness reported considerably better practices (OR = 8.24, 95% CI 1.72-39.63). Food handlers with one to five years of experience in the industry expressed notable willingness to take vaccination (OR = 7.71, 95% CI 1.79-33.18). Addressing poor HEV awareness and knowledge and poor practices against the disease is crucial in enlightening the policy makers about awareness among food handlers and general population. Nonetheless, a good immunization attitude, significant acceptance toward vaccination even with the vaccine being unavailable in Malaysia, and limited awareness of HEV highlight a promising development.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140023080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using big data to analyze the vaccination status of children with congenital heart disease in Yinzhou District, China. 利用大数据分析中国鄞州区先天性心脏病儿童的疫苗接种情况。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-11 DOI: 10.1080/21645515.2024.2319967
Lin Zhang, Ziliang Yang, Yueqi Yin, Wenzan Huang, Tianfei Yi, Jianming Ping, Liya Liu, Peng Shen, Yexiang Sun, Hongbo Lin

Congenital heart disease (CHD) represents a significant population warranting particular attention concerning vaccination coverage. To comprehend the vaccination status of CHD within Yinzhou District, Ningbo City, China, and to facilitate the formulation of preventive, control, and immunization strategies against vaccine-preventable diseases in children with congenital heart conditions. Using the China Yinzhou Electronic Health Record Study (CHERRY) database, we analyzed the vaccination coverage of children with CHD born between January 1, 2016 and September 20, 2021, and analyzed the influencing factors associated with the level of vaccination coverage. This study involved 762 children diagnosed with CHD at the age of 12 months, revealing that 86.74% of these children had received at least one dose of the National Immunization Program (NIP) vaccines. The coverage for non-NIP vaccines, such as the rotavirus vaccine, influenza vaccine, Influenza Haemophilus influenzae Type b (Hib) Conjugate Vaccine, 13-valent pneumococcal conjugate vaccine (PCV13), and inactivated enterovirus type 71 vaccine (EV71), stood at 27.30%, 7.74%, 63.25%, 33.76%, and 34.51%, respectively. The completion coverage for the entire vaccination schedule were 27.30%, 5.51%, 55.77%, 34.25%, and 25.59%, respectively. There was a statistically significant correlation between vaccination coverage in classification of diagnostic medical institutions and the types of diagnosed diseases. Compared to their typically developing counterparts, 12-month-old children afflicted with CHD exhibit a slightly diminished vaccination coverage, alongside a discernible inclination toward delayed vaccination. Notably, the determination to undergo vaccinations seems predominantly influenced by the classification of diagnostic medical institutions. In practical terms, proactive measures involving early diagnosis, comprehensive health assessments, and timely interventions ought to be implemented to enhance vaccination rates while prioritizing safety.

先天性心脏病(CHD)是一个需要特别关注疫苗接种率的重要人群。为了了解宁波市鄞州区先天性心脏病儿童的疫苗接种情况,帮助制定先天性心脏病儿童疫苗可预防疾病的预防、控制和免疫策略。我们利用中国鄞州电子健康档案研究(CHERRY)数据库,分析了2016年1月1日至2021年9月20日期间出生的先天性心脏病儿童的疫苗接种覆盖率,并分析了与疫苗接种覆盖率水平相关的影响因素。这项研究涉及 762 名在 12 个月大时被诊断为患有先天性心脏病的儿童,结果显示,其中 86.74% 的儿童至少接种过一剂国家免疫规划(NIP)疫苗。轮状病毒疫苗、流感疫苗、b 型流感嗜血杆菌 (Hib) 结合疫苗、13 价肺炎球菌结合疫苗 (PCV13) 和 71 型肠道病毒灭活疫苗 (EV71) 等非国家免疫计划疫苗的接种覆盖率分别为 27.30%、7.74%、63.25%、33.76% 和 34.51%。整个接种计划的完成覆盖率分别为 27.30%、5.51%、55.77%、34.25% 和 25.59%。据统计,医疗诊断机构分类中的疫苗接种覆盖率与诊断疾病类型之间存在明显的相关性。与发育正常的儿童相比,患有先天性心脏病的 12 个月大儿童的疫苗接种覆盖率略有下降,同时明显倾向于延迟接种疫苗。值得注意的是,是否接种疫苗似乎主要受诊断医疗机构分类的影响。在实际操作中,应采取包括早期诊断、全面健康评估和及时干预在内的积极措施来提高疫苗接种率,同时将安全性放在首位。
{"title":"Using big data to analyze the vaccination status of children with congenital heart disease in Yinzhou District, China.","authors":"Lin Zhang, Ziliang Yang, Yueqi Yin, Wenzan Huang, Tianfei Yi, Jianming Ping, Liya Liu, Peng Shen, Yexiang Sun, Hongbo Lin","doi":"10.1080/21645515.2024.2319967","DOIUrl":"10.1080/21645515.2024.2319967","url":null,"abstract":"<p><p>Congenital heart disease (CHD) represents a significant population warranting particular attention concerning vaccination coverage. To comprehend the vaccination status of CHD within Yinzhou District, Ningbo City, China, and to facilitate the formulation of preventive, control, and immunization strategies against vaccine-preventable diseases in children with congenital heart conditions. Using the China Yinzhou Electronic Health Record Study (CHERRY) database, we analyzed the vaccination coverage of children with CHD born between January 1, 2016 and September 20, 2021, and analyzed the influencing factors associated with the level of vaccination coverage. This study involved 762 children diagnosed with CHD at the age of 12 months, revealing that 86.74% of these children had received at least one dose of the National Immunization Program (NIP) vaccines. The coverage for non-NIP vaccines, such as the rotavirus vaccine, influenza vaccine, Influenza Haemophilus influenzae Type b (Hib) Conjugate Vaccine, 13-valent pneumococcal conjugate vaccine (PCV13), and inactivated enterovirus type 71 vaccine (EV71), stood at 27.30%, 7.74%, 63.25%, 33.76%, and 34.51%, respectively. The completion coverage for the entire vaccination schedule were 27.30%, 5.51%, 55.77%, 34.25%, and 25.59%, respectively. There was a statistically significant correlation between vaccination coverage in classification of diagnostic medical institutions and the types of diagnosed diseases. Compared to their typically developing counterparts, 12-month-old children afflicted with CHD exhibit a slightly diminished vaccination coverage, alongside a discernible inclination toward delayed vaccination. Notably, the determination to undergo vaccinations seems predominantly influenced by the classification of diagnostic medical institutions. In practical terms, proactive measures involving early diagnosis, comprehensive health assessments, and timely interventions ought to be implemented to enhance vaccination rates while prioritizing safety.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10936686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bidirectional crosstalk between the epithelial-mesenchymal transition and immunotherapy: A bibliometric study. 上皮-间充质转化与免疫疗法之间的双向交流:文献计量学研究。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-19 DOI: 10.1080/21645515.2024.2328403
Wei Du, Zemin Tang, Ashuai Du, Qinglong Yang, Rong Xu

Immunotherapy has recently attracted considerable attention. However, currently, a thorough analysis of the trends associated with the epithelial-mesenchymal transition (EMT) and immunotherapy is lacking. In this study, we used bibliometric tools to provide a comprehensive overview of the progress in EMT-immunotherapy research. A total of 1,302 articles related to EMT and immunotherapy were retrieved from the Web of Science Core Collection (WOSCC). The analysis indicated that in terms of the volume of research, China was the most productive country (49.07%, 639), followed by the United States (16.89%, 220) and Italy (3.6%, 47). The United States was the most influential country according to the frequency of citations and citation burstiness. The results also suggested that Frontiers in Immunotherapy can be considered as the most influential journal with respect to the number of articles and impact factors. "Immune infiltration," "bioinformatics analysis," "traditional Chinese medicine," "gene signature," and "ferroptosis" were found to be emerging keywords in EMT-immunotherapy research. These findings point to potential new directions that can deepen our understanding of the mechanisms underlying the combined effects of immunotherapy and EMT and help develop strategies for improving immunotherapy.

免疫疗法最近引起了广泛关注。然而,目前还缺乏对上皮-间质转化(EMT)和免疫疗法相关趋势的透彻分析。在本研究中,我们利用文献计量学工具全面概述了EMT-免疫疗法研究的进展。我们从科学网核心数据库(Web of Science Core Collection,WOSCC)共检索到 1302 篇与 EMT 和免疫疗法相关的文章。分析表明,就研究数量而言,中国的研究成果最多(49.07%,639篇),其次是美国(16.89%,220篇)和意大利(3.6%,47篇)。从被引频次和被引突发度来看,美国是最有影响力的国家。结果还表明,就文章数量和影响因子而言,《免疫疗法前沿》可被视为最有影响力的期刊。研究发现,"免疫浸润"、"生物信息学分析"、"传统中医"、"基因特征 "和 "铁瘤 "是EMT-免疫疗法研究中的新兴关键词。这些发现指出了潜在的新方向,可以加深我们对免疫疗法和EMT联合作用机制的理解,并有助于制定改善免疫疗法的策略。
{"title":"Bidirectional crosstalk between the epithelial-mesenchymal transition and immunotherapy: A bibliometric study.","authors":"Wei Du, Zemin Tang, Ashuai Du, Qinglong Yang, Rong Xu","doi":"10.1080/21645515.2024.2328403","DOIUrl":"10.1080/21645515.2024.2328403","url":null,"abstract":"<p><p>Immunotherapy has recently attracted considerable attention. However, currently, a thorough analysis of the trends associated with the epithelial-mesenchymal transition (EMT) and immunotherapy is lacking. In this study, we used bibliometric tools to provide a comprehensive overview of the progress in EMT-immunotherapy research. A total of 1,302 articles related to EMT and immunotherapy were retrieved from the Web of Science Core Collection (WOSCC). The analysis indicated that in terms of the volume of research, China was the most productive country (49.07%, 639), followed by the United States (16.89%, 220) and Italy (3.6%, 47). The United States was the most influential country according to the frequency of citations and citation burstiness. The results also suggested that <i>Frontiers in Immunotherapy</i> can be considered as the most influential journal with respect to the number of articles and impact factors. \"Immune infiltration,\" \"bioinformatics analysis,\" \"traditional Chinese medicine,\" \"gene signature,\" and \"ferroptosis\" were found to be emerging keywords in EMT-immunotherapy research. These findings point to potential new directions that can deepen our understanding of the mechanisms underlying the combined effects of immunotherapy and EMT and help develop strategies for improving immunotherapy.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China. 一项 3 期随机、开放标签研究,评估在中国健康婴儿中同时和交错接种五价轮状病毒活疫苗和脊髓灰质炎灭活疫苗的免疫原性和安全性。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-03-20 DOI: 10.1080/21645515.2024.2324538
Shaomin Chen, Zhifang Ying, Yan Liu, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, Yong Zhang, Guixiu Liu, Weiwei Zhao, Rong Fu, Qiong Shou, Minghuan Zheng, Xueyan Liao, Yingmei Tu, Jon Stek, Jonathan Hartzel, Changgui Li, Jikai Zhang

This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants. The primary objective was the non-inferiority of neutralizing antibody (nAb) responses in the concomitant- versus the staggered-use groups. Antibody responses were measured at baseline and 1-month post-dose 3 (PD3). Parents/legal guardians recorded adverse events for 30 or 15 d after study vaccinations in the concomitant-use or staggered-use groups, respectively. At PD3, >98% of participants seroconverted to all three poliovirus types, and the primary objective was met as lower bounds of the two-sided 95% CI for between-group difference in nAb seroconversion percentages ranged from - 4.3% to - 1.6%, for all poliovirus types, p < .001. At PD3, geometric mean titers (GMTs) of nAb responses to poliovirus types 1, 2, and 3 in the concomitant-use group and the staggered-use group were comparable; 100% of participants had nAb titers ≥1:8 and ≥1:64 for all poliovirus types. Anti-rotavirus serotype-specific IgA GMTs and participants with ≥3-fold rise in postvaccination titers from baseline were comparable between groups. Administration of RV5 and IPV was well tolerated with comparable safety profiles in both groups. The immunogenicity of IPV in the concomitant-use group was non-inferior to the staggered-use group and RV5 was immunogenic in both groups. No safety concerns were identified. These data support the concomitant use of RV5 and IPV in healthy Chinese infants.

这项在中国进行的开放标签、随机、3 期研究(V260-074;NCT04481191)评估了在 400 名健康婴儿中同时接种和交错接种三剂口服五价轮状病毒活疫苗 (RV5) 和三剂肌肉注射脊髓灰质炎灭活疫苗 (IPV) 的免疫原性和安全性。首要目标是中和抗体 (nAb) 反应在同时接种组和错开接种组中的非劣效性。抗体反应在基线和剂量 3 (PD3) 后 1 个月进行测量。同时接种组或错开接种组的家长/法定监护人分别记录了研究接种后 30 天或 15 天的不良事件。在 PD3 时,超过 98% 的参与者对所有三种脊灰病毒类型都发生了血清转换,达到了主要目标,因为所有脊灰病毒类型的 nAb 血清转换百分比组间差异的双侧 95% CI 下限为 - 4.3% 至 - 1.6%,p<0.05,即 nAb 血清转换百分比组间差异的双侧 95% CI 下限为 - 4.3% 至 - 1.6%,p<0.05,即 nAb 血清转换百分比组间差异的双侧 95% CI 下限为 - 1.5%。
{"title":"A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.","authors":"Shaomin Chen, Zhifang Ying, Yan Liu, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, Yong Zhang, Guixiu Liu, Weiwei Zhao, Rong Fu, Qiong Shou, Minghuan Zheng, Xueyan Liao, Yingmei Tu, Jon Stek, Jonathan Hartzel, Changgui Li, Jikai Zhang","doi":"10.1080/21645515.2024.2324538","DOIUrl":"10.1080/21645515.2024.2324538","url":null,"abstract":"<p><p>This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants. The primary objective was the non-inferiority of neutralizing antibody (nAb) responses in the concomitant- versus the staggered-use groups. Antibody responses were measured at baseline and 1-month post-dose 3 (PD3). Parents/legal guardians recorded adverse events for 30 or 15 d after study vaccinations in the concomitant-use or staggered-use groups, respectively. At PD3, >98% of participants seroconverted to all three poliovirus types, and the primary objective was met as lower bounds of the two-sided 95% CI for between-group difference in nAb seroconversion percentages ranged from - 4.3% to - 1.6%, for all poliovirus types, <i>p</i> < .001. At PD3, geometric mean titers (GMTs) of nAb responses to poliovirus types 1, 2, and 3 in the concomitant-use group and the staggered-use group were comparable; 100% of participants had nAb titers ≥1:8 and ≥1:64 for all poliovirus types. Anti-rotavirus serotype-specific IgA GMTs and participants with ≥3-fold rise in postvaccination titers from baseline were comparable between groups. Administration of RV5 and IPV was well tolerated with comparable safety profiles in both groups. The immunogenicity of IPV in the concomitant-use group was non-inferior to the staggered-use group and RV5 was immunogenic in both groups. No safety concerns were identified. These data support the concomitant use of RV5 and IPV in healthy Chinese infants.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of risk perception and institutional trust on COVID-19 vaccine hesitancy in China. 风险认知和机构信任对中国 COVID-19 疫苗接种犹豫不决的影响。
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-01-28 DOI: 10.1080/21645515.2024.2301793
Guiwu Chen, Yiyun Yao, Yaowen Zhang, Fei Zhao

Vaccination has become the primary means for citizens to prevent severe morbidity and mortality during the pandemic. However, vaccine hesitancy poses a major threat to global public health security. Based on the data from Chinese General Social Survey in 2021, this study aims to explore the socio-political aspects of COVID-19 vaccine hesitancy, focusing on the relationship between COVID-19 risk perceptions, institutional trust and vaccine hesitancy. Among the samples, 39.8% of the respondents exhibited COVID-19 vaccine hesitancy, 48.9% had a high awareness of the risk of COVID-19, and 74.6% presented a high level of trust in institutions. The results showed that higher risk perception and institutional trust are negatively correlated with vaccine hesitancy (p < .001). Institutional trust had no statistically significant moderating effect on the association between risk perception and vaccine hesitancy, but the role of institutional trust in influencing vaccine hesitancy is more significant at a lower level of perceptions of COVID-19 risk. Furthermore, regional variations in the factors contributing to vaccine hesitancy were demonstrated in China. These findings have important implications for developing strategies to address vaccine hesitancy.

接种疫苗已成为公民在大流行病期间预防严重发病和死亡的主要手段。然而,对疫苗的犹豫不决对全球公共卫生安全构成了重大威胁。本研究基于 2021 年中国社会综合调查数据,旨在探讨 COVID-19 疫苗接种犹豫的社会政治因素,重点关注 COVID-19 风险认知、制度信任与疫苗接种犹豫之间的关系。在样本中,39.8% 的受访者表现出 COVID-19 疫苗犹豫,48.9% 的受访者对 COVID-19 的风险认知度较高,74.6% 的受访者对机构的信任度较高。结果显示,较高的风险意识和机构信任度与疫苗犹豫不决呈负相关(p
{"title":"The impact of risk perception and institutional trust on COVID-19 vaccine hesitancy in China.","authors":"Guiwu Chen, Yiyun Yao, Yaowen Zhang, Fei Zhao","doi":"10.1080/21645515.2024.2301793","DOIUrl":"10.1080/21645515.2024.2301793","url":null,"abstract":"<p><p>Vaccination has become the primary means for citizens to prevent severe morbidity and mortality during the pandemic. However, vaccine hesitancy poses a major threat to global public health security. Based on the data from Chinese General Social Survey in 2021, this study aims to explore the socio-political aspects of COVID-19 vaccine hesitancy, focusing on the relationship between COVID-19 risk perceptions, institutional trust and vaccine hesitancy. Among the samples, 39.8% of the respondents exhibited COVID-19 vaccine hesitancy, 48.9% had a high awareness of the risk of COVID-19, and 74.6% presented a high level of trust in institutions. The results showed that higher risk perception and institutional trust are negatively correlated with vaccine hesitancy (<i>p</i> < .001). Institutional trust had no statistically significant moderating effect on the association between risk perception and vaccine hesitancy, but the role of institutional trust in influencing vaccine hesitancy is more significant at a lower level of perceptions of COVID-19 risk. Furthermore, regional variations in the factors contributing to vaccine hesitancy were demonstrated in China. These findings have important implications for developing strategies to address vaccine hesitancy.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revamping the BCG revaccination strategy: Records to recall, or just call it phoenix? 改革卡介苗接种策略:记录召回,还是凤毛麟角?
IF 4.8 4区 医学 Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-31 Epub Date: 2024-01-29 DOI: 10.1080/21645515.2023.2300158
Paulo R Z Antas, Mario A Flores-Valdez, Camille Locht
{"title":"Revamping the BCG revaccination strategy: Records to recall, or just call it phoenix?","authors":"Paulo R Z Antas, Mario A Flores-Valdez, Camille Locht","doi":"10.1080/21645515.2023.2300158","DOIUrl":"10.1080/21645515.2023.2300158","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Vaccines & Immunotherapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1